An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design

Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).

Yazar Ertas, Faruk
Kaya, Hasan
Yildiz, Abdulkadir
Davutoglu, Vedat
Kiris, Abdulkadir
Dinc, Lale
Kafes, Habibe
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/2047
Tek Biçim Adres 10.5543/tkda.2015.35984
Konu Başlıkları Anticoagulant agent
atrial fibrillation/epidemiology
drug utilization
electrocardiography
international normalized ratio
warfarin
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
Dergi Cilt Bilgisi 43
Dergi Sayısı 2
Sayfalar 169 - 177
Yayın Yılı 2015
Eser Adı
[dc.title]
An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design
Yazar
[dc.contributor.author]
Ertas, Faruk
Yazar
[dc.contributor.author]
Kaya, Hasan
Yazar
[dc.contributor.author]
Yildiz, Abdulkadir
Yazar
[dc.contributor.author]
Davutoglu, Vedat
Yazar
[dc.contributor.author]
Kiris, Abdulkadir
Yazar
[dc.contributor.author]
Dinc, Lale
Yazar
[dc.contributor.author]
Kafes, Habibe
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
TURKISH SOC CARDIOLOGY
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).
Açıklama
[dc.description]
WOS: 000421963600007
Açıklama
[dc.description]
PubMed: 25782122
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Anticoagulant agent
Konu Başlıkları
[dc.subject]
atrial fibrillation/epidemiology
Konu Başlıkları
[dc.subject]
drug utilization
Konu Başlıkları
[dc.subject]
electrocardiography
Konu Başlıkları
[dc.subject]
international normalized ratio
Konu Başlıkları
[dc.subject]
warfarin
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1016-5169
İlk Sayfa Sayısı
[dc.identifier.startpage]
169
Son Sayfa Sayısı
[dc.identifier.endpage]
177
Dergi Adı
[dc.relation.journal]
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
43
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.5543/tkda.2015.35984
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/2047
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
20
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
13 Şubat 2024 19:58
Google Kontrol
Tıklayınız
patients vitamin antagonist management modality attack non-valvular cardiovascular ischemic stroke bleeding evaluated expected cardiac points Results (death thromboembolism hospitalization) transient systemic results Objectives end-points adverse NCT02354456 number ClinicalTrials (AFTER-2 detected predictors independent (MACEs) events available
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms